GT201400225A - Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b.16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino - Google Patents

Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b.16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino

Info

Publication number
GT201400225A
GT201400225A GT201400225A GT201400225A GT201400225A GT 201400225 A GT201400225 A GT 201400225A GT 201400225 A GT201400225 A GT 201400225A GT 201400225 A GT201400225 A GT 201400225A GT 201400225 A GT201400225 A GT 201400225A
Authority
GT
Guatemala
Prior art keywords
methyl
espirox
onas
treatment
menorragy
Prior art date
Application number
GT201400225A
Other languages
English (en)
Inventor
Norbert Schmees
Lars Ròse
Katja Prelle
Dr Reinhand Nubbemeyer
Tuula Valo
Henriika Korolainen
Harri Jukarainen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48141995&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT201400225A publication Critical patent/GT201400225A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE DESCRIBE EL USO INTRAUTERINO DE 18-METIL-15B,16B-METILEN-19-NOR-20-ESPIROX-4-EN-3-ONAS DE LA FÓRMULA GENERAL (1) EN DONDE R<6> Y R<7> REPRESENTAN HIDRÓGENO O UN GRUPO METILENO, EN LA TERAPIA DE LA MENORRAGIA, EN GENERAL DE SANGRADOS UTERINOS, ASÍ COMO UN SISTEMA INTRAUTERINO PARA LA APLICACIÓN MENCIONADA QUE CONTIENE UN COMPUESTO DE LA FÓRMULA (1).
GT201400225A 2012-04-23 2014-10-23 Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b.16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino GT201400225A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102012206653 2012-04-23

Publications (1)

Publication Number Publication Date
GT201400225A true GT201400225A (es) 2016-01-22

Family

ID=48141995

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400225A GT201400225A (es) 2012-04-23 2014-10-23 Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b.16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino

Country Status (28)

Country Link
US (1) US20150119372A1 (es)
EP (1) EP2841073A1 (es)
JP (1) JP2015514789A (es)
KR (1) KR20150005548A (es)
CN (1) CN104379149A (es)
AR (1) AR090800A1 (es)
AU (1) AU2013251842A1 (es)
BR (1) BR112014026086A2 (es)
CA (1) CA2871001A1 (es)
CL (1) CL2014002857A1 (es)
CO (1) CO7111253A2 (es)
CR (1) CR20140489A (es)
CU (1) CU20140120A7 (es)
DO (1) DOP2014000240A (es)
EA (1) EA201491917A1 (es)
EC (1) ECSP14024263A (es)
GT (1) GT201400225A (es)
HK (1) HK1206271A1 (es)
IL (1) IL235096A0 (es)
MA (1) MA37443A1 (es)
MX (1) MX2014012848A (es)
PE (1) PE20142437A1 (es)
PH (1) PH12014502371A1 (es)
SG (1) SG11201406583QA (es)
TN (1) TN2014000445A1 (es)
TW (1) TW201345530A (es)
UY (1) UY34759A (es)
WO (1) WO2013160200A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90627C (fi) 1992-07-31 1994-03-10 Leiras Oy Laitteisto lääkeainesauvan varustamiseksi vaipalla
PH30867A (en) 1992-07-31 1997-12-09 Leiras Oy Method and equipment for installing a medicine capsule on a support.
FI107339B (fi) 1998-06-30 2001-07-13 Leiras Oy Lääkeaineiden läpäisynopeutta säätävä kalvo tai matriisi
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate

Also Published As

Publication number Publication date
US20150119372A1 (en) 2015-04-30
CR20140489A (es) 2014-12-24
UY34759A (es) 2013-11-29
WO2013160200A1 (de) 2013-10-31
PE20142437A1 (es) 2015-01-31
CA2871001A1 (en) 2013-10-31
AR090800A1 (es) 2014-12-10
CU20140120A7 (es) 2015-02-26
DOP2014000240A (es) 2015-02-15
TN2014000445A1 (en) 2016-03-30
AU2013251842A1 (en) 2014-11-06
MA37443A1 (fr) 2016-05-31
PH12014502371A1 (en) 2015-01-12
MX2014012848A (es) 2015-02-05
CL2014002857A1 (es) 2015-02-06
ECSP14024263A (es) 2015-12-31
TW201345530A (zh) 2013-11-16
BR112014026086A2 (pt) 2017-07-18
SG11201406583QA (en) 2014-11-27
CO7111253A2 (es) 2014-11-10
CN104379149A (zh) 2015-02-25
IL235096A0 (en) 2014-12-31
EP2841073A1 (de) 2015-03-04
KR20150005548A (ko) 2015-01-14
JP2015514789A (ja) 2015-05-21
HK1206271A1 (en) 2016-01-08
EA201491917A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
UY35500A (es) Indazoles sustituidos con heteroarilo
CL2016002312A1 (es) Modulador del receptor de andrógeno y usos de este.
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CL2015003801A1 (es) Formulaciones de anticuerpos y metodos
CL2012002189A1 (es) Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
ECSP13012519A (es) Compuestos sustituidos de benzamida
CL2016001076A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolosis.
GT201400090A (es) 2-tiopirimidinonas
UY34725A (es) Nuevos derivados de tienopirimidina, procesos para su preparación y sus usos terapéuticos.
UY35499A (es) Indazoles sustituidos con diaminoheteroarilo
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
CL2016001210A1 (es) Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis.
CR20160176A (es) Sistema de administración intrauterina
GT201400146A (es) Composiciones farmacéuticas tópicas que comprenden bexaroteno y corticosteroides
GT201400225A (es) Uso de 18-metil-15b,16b-metilen-19-nor-20-espirox-4-en-3-onas en el tratamiento de menorragia, y sistemas intrauterinos que comprenden 18-metil-15b.16b-metilen-19-nor-20-espirox-4-en-3-onas para el tratamiento de trastornos con sangrado uterino
DOP2014000241A (es) USO INTRAUTERINO DE 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, SISTEMAS INTRAUTERINOS QUE CONTIENEN 18–METIL–15ß,16ߖMETILEN–19–NOR–20–ESPIROX–4–EN–3–ONAS, ASÍ COMO SU USO EN LA ANTICONCEPCIÓN Y TERAPIA GINECOLÓGICA
AR098060A1 (es) Sistema de administración intrauterina